Welcome to our dedicated page for Gelteq news (Ticker: GELS), a resource for investors and traders seeking the latest updates and insights on Gelteq stock.
Gelteq Limited develops gel-based oral delivery systems for prescription drugs, nutraceuticals, pet care, sports, over-the-counter and other product categories. The company focuses on edible gel dosage formats and proprietary formulations designed for oral delivery, including white-label manufacturing and out-licensing of its technology to commercial partners.
GELS news commonly covers preclinical bioavailability and absorption studies, applications for water-soluble, oil-soluble and poorly soluble compounds, and medicinal cannabinoid delivery through the company’s oral gel platform. Updates also include nutraceutical product commercialization, distribution arrangements, sports-performance formulations, manufacturing partnerships and international market expansion.
Gelteq (NASDAQ:GELS) issued a corporate update highlighting clinical, commercial and financing progress in 2026.
Key developments include a commenced veterinary antiparasitic clinical trial with a planned FDA application in 2026, a first human clinical trial expected to start next quarter, and a preclinical diabetes study now underway.
Gelteq is expanding its API and peptide-based oral delivery pipeline, completed canine palatability trials with Kemin Industries, manufactured a commercial product for a new East Asian customer for June 2026 delivery, established a Center of Excellence in Guangdong, China, and secured up to US$3.5 million in strategic debt financing, with US$1 million already funded and a further US$2.5 million subject to shareholder approval on June 18, 2026.
Gelteq (ASX:GELS) reported successful completion of veterinary palatability trials with Kemin Industries, validating its Gelteq® gel-based delivery platform for animal health. The studies showed strong canine acceptance and effective masking of bitter flavours, supporting use in veterinary pharmaceuticals and potential partnerships across animal health and pharmaceutical sectors.
Gelteq (GELS) announced a new Gelteq Center of Excellence in Guangdong Province, China, creating a strategic regional hub within a major pharma and biotech ecosystem.
The hub is expected to support accelerated product development and commercialization, expanded formulation and testing capabilities, and greater capacity to advance multiple programs, strengthening Gelteq’s globally integrated platform and international commercial expansion.
Gelteq (ASX:GELS) has begun its first clinical trial for an antiparasitic drug candidate using Gelteq® technology in the veterinary sector. The study is intended to support an FDA regulatory pathway for animal use, with a potential application targeted later in 2026.
The trial aims to generate data on safety, efficacy and formulation performance in animal health. According to Gelteq, this builds on prior FDA suitability petition acceptance and aligns with its dual-track strategy alongside its commercial nutraceutical portfolio.
Healthy Extracts (OTCQB:GELS) reported record Q1 2026 net revenue of $1.6 million, up 73% year over year, driven largely by the Gummy USA merger and broader distribution.
Gross profit rose 133% to $989,000 with 61.4% margin, net loss narrowed to $201,000, and EBITDA turned positive at $40,500. Management is targeting 2026 net revenue above $20 million, supported by a major Imaraïs Beauty manufacturing partnership and Gummy USA’s facility, which is expected to reach its $20 million annual production capacity.
Gelteq (ASX:GELS) arranged up to USD $3.5 million in strategic debt financing to fund commercialization, expand clinical trials and support revenue-generating opportunities. The facility provides $1 million at closing and a further $2.5 million subject to shareholder approval expected in June 2026.
The structure includes at least six months with no repayments, which Gelteq believes will preserve operational runway while it scales pharmaceutical and nutraceutical programs and accelerates sales execution across key markets.
Healthy Extracts (OTCQB:GELS) reported preliminary unaudited 2025 results showing net revenue up 45% to $4.5 million, driven by the Gummy USA merger, product launches, and channel expansion. Organic operations grew ~25% and subscription channels rose substantially, while management projects the new facility could reach a $20 million annual capacity in 2026.
Results are preliminary and subject to audit and revision before the company's Form 10-K filing.
Gelteq (ASX:GELS) and Healthy Extracts signed a Memorandum of Understanding on February 11, 2026 to enable U.S. manufacturing and global distribution of Gelteq’s proprietary gel-based nutraceutical formulations.
Healthy Extracts will manufacture, commercialise and distribute US-made gel products while Gelteq retains IP and provides technical transfer.
Gelteq (GELS) announced positive preclinical results on Jan 13, 2026 showing its oral gel delivery platform increased cannabidiol (CBD) absorption versus an FDA-approved oil product. Gelteq reported a greater than 22% increase in bioavailability and a higher peak exposure despite using a lower CBD concentration. The company says the platform enables precise, pre-measured dosing, faster uptake, and a non-invasive alternative to vaping.
Gelteq highlighted the Special Access Scheme (SAS) as a potential expedited pathway to earlier patient access in Australia and a stepping stone for global commercial partnerships and licensing opportunities.
Gelteq (NASDAQ:GELS) announced a partnership with the Hong Kong Flag Football Program on Dec 16, 2025 to integrate its gel-based hydration and sports performance formulations into men’s, women’s and youth national team training and competition.
The announcement cites recent regional commercial progress, including a China-focused sales agreement with Shenzhen Mana Health Management that carries minimum annual order commitments of at least USD $1.3 million. Gelteq noted prior adoption across Australia and Asia, including league-wide use on the Professional Pickleball Association’s PPA Tour Australia.